Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1957 3
1958 1
1960 1
1961 1
1962 1
1963 2
1964 8
1965 4
1966 6
1967 6
1968 8
1969 13
1970 13
1971 4
1972 5
1973 6
1974 6
1975 7
1976 9
1977 6
1978 6
1979 12
1980 11
1981 13
1982 4
1983 5
1984 15
1985 20
1986 16
1987 16
1988 22
1989 28
1990 21
1991 35
1992 22
1993 40
1994 50
1995 38
1996 35
1997 42
1998 44
1999 50
2000 38
2001 42
2002 46
2003 45
2004 25
2005 28
2006 26
2007 37
2008 37
2009 40
2010 50
2011 30
2012 44
2013 33
2014 48
2015 46
2016 46
2017 55
2018 66
2019 67
2020 74
2021 97
2022 84
2023 53
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

1,709 results

Results by year

Filters applied: . Clear all
Page 1
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, Abe M, Kaneda Y, Maeda N, Shiose Y, Iguchi T, Ishizaka T, Karibe T, Hayakawa I, Morita K, Nakada T, Nomura T, Wakita K, Kagari T, Abe Y, Murakami M, Ueno S, Agatsuma T. Hashimoto Y, et al. Among authors: koyama k. Clin Cancer Res. 2019 Dec 1;25(23):7151-7161. doi: 10.1158/1078-0432.CCR-19-1745. Epub 2019 Aug 30. Clin Cancer Res. 2019. PMID: 31471314
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. Among authors: koyama k. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M.
Abe H, Takeda N, Isagawa T, Semba H, Nishimura S, Morioka MS, Nakagama Y, Sato T, Soma K, Koyama K, Wake M, Katoh M, Asagiri M, Neugent ML, Kim JW, Stockmann C, Yonezawa T, Inuzuka R, Hirota Y, Maemura K, Yamashita T, Otsu K, Manabe I, Nagai R, Komuro I. Abe H, et al. Among authors: koyama k. Nat Commun. 2019 Jun 27;10(1):2824. doi: 10.1038/s41467-019-10859-w. Nat Commun. 2019. PMID: 31249305 Free PMC article.
Tumor-resident intracellular bacteria benefit metastasis.
Koyama K, Inamura K. Koyama K, et al. Ann Transl Med. 2023 Aug 30;11(10):376. doi: 10.21037/atm-22-6209. Epub 2023 May 6. Ann Transl Med. 2023. PMID: 37675301 Free PMC article. No abstract available.
Middle meatus microbiome in patients with eosinophilic chronic rhinosinusitis in a Japanese population.
Kidoguchi M, Imoto Y, Noguchi E, Nakamura T, Morii W, Adachi N, Ii R, Koyama K, Aoki S, Miyashita K, Hosokawa Y, Omura K, Tanaka Y, Tanaka K, Hida Y, Ninomiya T, Kato Y, Sakashita M, Takabayashi T, Fujieda S. Kidoguchi M, et al. Among authors: koyama k. J Allergy Clin Immunol. 2023 Dec;152(6):1669-1676.e3. doi: 10.1016/j.jaci.2023.06.029. Epub 2023 Sep 26. J Allergy Clin Immunol. 2023. PMID: 37768238
1,709 results